Introduction
The failure of modern medicine to eliminate tuberculosis, despite the availability of effective treatment, may be one of the greatest missed opportunities of our time. Worldwide, this disease remains the leading cause of death from an infectious organism, especially among children in developing countries. Despite important advances in recent years, children and adults continue to die of this disease. New concerns including globalization, rising rates of disease among certain populations, the emergence and spread of multidrug-resistant strains, the increased susceptibility of individuals infected with HIV, and the unmanageable cost of treating tuberculosis in the developing world, have led to public health crises in many areas.
Young children, especially infants, are the most vulnerable to tuberculosis, and may experience rapidly progressive, sometimes unrecognized, disease leading to death. Congenital disease, an exceedingly rare manifestation of tuberculosis, has been reported about 300 times in the world literature [1] . Not surprisingly, most of the literature consists of individual case reports, case series and reviews.
The recognition of tuberculosis in infants and pregnant women can be dif®cult because symptoms are often absent or nonspeci®c. Also, most of the currently available diagnostic tests for tuberculosis have low sensitivity in children. Prompt treatment is required for the survival of infants with congenital tuberculosis; therefore, physicians caring for pregnant women, children, or neonates must be aware of the presentation of this disease and its potential impact on women of childbearing age and on their newborn infants.
Epidemiology
A worldwide resurgence of tuberculosis occurred between 1985 and 1993. Since 1992, the distribution of tuberculosis cases according to age, ethnicity and country of birth has changed dramatically in developed countries, with case rates rising among recent immigrants and their children but falling in all other groups [2] . A 1998 national survey in England and Wales [3 . ] found that over 50% of those with tuberculosis were born outside these countries, 39% coming from India and 13% from Africa. The median age for disease in these patients was less than 30 years; this compares with an age of more than 50 years in the white population. These differences may, in part, be attributed to higher rates of human immunode®ciency disease, lower socioeconomic conditions, and other risk factors for tuberculosis in immigrant populations. However, one study in Leeds, UK [4 . ], found ethnicity to be the leading risk factor for tuberculosis, independent of lower socioeconomic conditions. The higher rate of tuberculosis among pregnant women and children from ethnic minority groups in developed countries is due to shifting epidemiological trends. Techniques including DNA ®ngerprinting [5, 6] and spoligotyping [7] of mycobacteria are new strategies used for detecting epidemiological links at the molecular level.
In developing countries, tuberculosis remains a major public health threat. Cases continue to rise unchecked in areas with high rates of infection with HIV due to increased susceptibility to disease. A study in Zambia [8] found an eightfold increase in maternal mortality at a teaching hospital over the past two decades, mainly because of nonobstetric causes of death including malaria (30%) and tuberculosis (25%). Ninety-two percent of the women with tuberculosis-related deaths in this study had HIV coinfection. In developing countries with high rates of tuberculosis, congenital tuberculosis may be under-recognized and underreported because of limited diagnostic technology as well as the nonspeci®c clinical features in pregnant women and neonates with tuberculosis.
Congenital tuberculosis
Congenital tuberculosis is exceedingly rare. Infection of the fetus can occur via direct spread through the umbilical cord, by aspiration or swallowing of infected amniotic¯uid, or by direct contact with maternal genital lesions during delivery [9] . During pregnancy, dissemination to the fetus is unusual, especially if the mother is taking effective treatment. More commonly, young infants with tuberculosis become infected after birth, through exposure to family or household members with contagious pulmonary disease.
In 1935, Beitzke [10] ®rst suggested diagnostic criteria for distinguishing congenital tuberculosis from postnatally acquired disease. Developed prior to the availability of antimicrobial therapy, these criteria were based mainly on post-mortem ®ndings. In 1994, a landmark article by Cantwell et al.
[11] suggested revised criteria requiring documentation of tuberculosis lesions in the infant and at least one of the following: (1) lesions in the ®rst week of life; (2) a primary hepatic complex or caseating granulomas; (3) documented tuberculosis infection of the endometrium or placenta; or (4) exclusion of tuberculosis infection after birth from the mother and other sources. While these criteria serve epidemiological and academic purposes, the distinction between congenital tuberculosis and postnatally acquired disease in neonates has little practical signi®cance, since the clinical manifestations, treatment and prognosis are the same.
Clinical presentation in pregnant women and neonates
An excellent review by Ormerod [12
. . ] discusses the clinical presentation and treatment of tuberculosis in pregnancy, as well as congenital disease. The question as to whether or not pregnancy makes tuberculosis disease more likely has been debated, especially during the last century [12
. . ]. Studies within the past 25 years have found no evidence that pregnancy increases the risk of tuberculosis [13] , even in women infected with HIV relative to non-pregnant women with HIV [14] .
The clinical presentation of tuberculosis in pregnant women is similar to that in non-pregnant individuals, although some studies have found fewer or less pronounced symptoms during pregnancy [15] . As fatigue and malaise are commonly experienced during pregnancy, clinicians may dismiss these symptoms of tuberculosis. Also, the diagnosis may be delayed because of the tendency to postpone radiographic studies. As with the general population, pulmonary disease is the most common form of tuberculosis during pregnancy. However, in a prospective case series in London in which 13 women were followed for 30 months, more extrapulmonary disease, fewer symptoms, recent immigration, and delays in diagnosis were found to be more common among pregnant women with tuberculosis than among non-pregnant women with tuberculosis [16] . Failure to diagnose tuberculosis during pregnancy makes the recognition of congenital disease more challenging. A high index of suspicion should be entertained when evaluating ill infants born to women at high risk for tuberculosis.
A number of case reports and reviews on congenital tuberculosis have been published in recent years [11, 17± 21] . As highlighted in these reports, the non-speci®c symptoms of congenital tuberculosis often mimic more common neonatal diseases such as bacterial sepsis or congenital viral infections [22 . ]. Symptoms may be evident at birth but are usually present at 2±3 weeks of age. The tuberculin skin test is universally negative in neonates at initial presentation, but usually converts to a positive result months later. The course of tuberculosis in the newborn infant usually leads to dissemination and fatal disease if not treated. The lungs and liver are most frequently involved, usually with a miliary pattern, though widespread disease can involve any organ system. The most common clinical signs and symptoms found in neonates with congenital tuberculosis are described in Table 1 [11]. Tuberculosis should be considered in an ill neonate with a poor response to conventional antibiotic therapy, especially if the mother has risk factors for tuberculosis [9, 22 . ]. Although slightly less sensitive than traditional solid media, BACTEC has shortened the time from specimen submission to culture results from 6±8 weeks (with solid media) to 1±2 weeks (with BACTEC). Antimicrobial sensitivity testing can also be performed with BACTEC, yielding results within 1±2 months of specimen submission, rather than the 3±4 months required with solid media. Nucleic acid ampli®cation techniques such as the polymerase chain reaction rapidly replicate speci®c target sequences of DNA or RNA in clinical specimens, which can then be identi®ed using a probe. The results of a polymerase chain reaction are usually available within 48 h. New techniques for rapid detection of drug resistance will be especially helpful in areas with high rates of multidrug-resistant tuberculosis. One such test is the line-probe assay, which detects rifampin-resistance mutations in the rpoB gene and is commercially available in Europe [25] . Because of the low sensitivity of many diagnostic tests for tuberculosis, a negative test result does not exclude the diagnosis, especially in children. Clinical criteria remain the`gold standard' for diagnosing tuberculosis. Better diagnostic tests are clearly needed.
Diagnostic tests
Testing for tuberculosis in children has traditionally been problematic, since children have lower bacillary loads than adults. Therefore, in children, detection of mycobacterial organisms is dif®cult using an acid-fast bacilli (AFB) smear, a polymerase chain reaction, or culture [26 . ]. Clinical studies have shown that even with three early-morning gastric aspirate specimens carefully obtained in the hospital, only 40±44% of clinically diagnosed children will have positive cultures for tuberculosis, and only 5±12% will be positive by AFB smear [27,28
. . ]. A recent study comparing the polymerase chain reaction, Amplicor (Roche Diagnostics, Basel, Switzerland), AFB smears, and traditional culture with clinical diagnosis in children found a sensitivity of 60% and a speci®city of 97% for the polymerase chain reaction [28
. . ]. Results for specimens obtained from children by bronchoalveolar lavage were similar to those for specimens obtained by gastric aspiration, showing that there is no advantage in using this more invasive technique. Compared to older children, infants with the disease are more likely to yield positive cultures (70%) and AFB smear results [29] . The higher yield in tuberculosis cultures from infants results from the fact that the disease is more widely disseminated and rapidly progressive (leading to higher bacillary loads) in infants than in older children. The higher sensitivity of cultures and AFB smears in neonates helps in the detection of congenital tuberculosis, yet the nonspeci®c clinical presentation can still make the diagnosis dif®cult in many cases. 
Prevention
The best way to prevent congenital tuberculosis in newborn infants is to treat and prevent the disease in pregnant women. pregnancy remains controversial. Arguments have been made on both sides of the issue: some people advocate treatment during pregnancy [41] , while others support the delay of treatment until months after delivery. A retrospective study in 1989 [42] found a 2.5-fold increase in isoniazid-induced hepatitis, and a fourfold higher death rate, among pregnant and postpartum Hispanic women treated for latent tuberculosis infection relative to non-pregnant women. The differences were not statistically signi®cant, but, on the basis of these ®ndings, some of®cial guidelines continue to recommend delay of treatment until after the postpartum period [43] . More recent studies suggest a much lower mortality, with a true isoniazid-associated death rate of 0.001% [44] . No controlled prospective trials have been conducted to address questions regarding isoniazid and hepatotoxicity in pregnant women. Using a decisionanalysis model, a recent publication [45] found improved health outcomes and reduced costs for women treated with isoniazid for latent tuberculosis infection during pregnancy. The American Thoracic Society and the Centers for Disease Control and Prevention recently published new guidelines [46] on the treatment of latent tuberculosis infection, which include recommendations for the treatment of women during pregnancy; these suggest careful monitoring for signs and symptoms of hepatitis. As tuberculosis rates continue to fall in developed countries, more emphasis will be directed towards treatment of latent infection.
Public health practices, including directly observed therapy, contact investigation of newly reported adult cases, and prophylaxis for young children exposed to tuberculosis, are important in preventing perinatal and childhood tuberculosis. In the USA, isoniazid is recommended, after a medical evaluation has excluded disease, in children under 4 years of age following exposure to contagious tuberculosis [47] . The British Thoracic Society guidelines [48] recommend chemoprophylaxis to all contacts of less than 2 years of age, irrespective of skin-test reactions. Incomplete contact investigation or failure to prescribe chemoprophylaxis may lead to missed opportunities for the prevention of tuberculosis in young children [49,50 . ]. A study in California between 1985 and 1994 [51] found that 40% of tuberculosis cases in children could have been prevented with improved contact investigation. Good public health practices are important in preventing disease in infants and young children.
The bacille Calmette±Gue Â rin vaccine has failed to control tuberculosis, despite its widespread use. While this vaccine appears to have good protective ef®cacy against disseminated disease in infants [52] , it does not prevent congenital tuberculosis, infection or active disease in most recipients. A recent meta-analysis estimated the overall ef®cacy of bacille Calmette±Gue Â rin vaccine to be around 50% [53] .
New vaccine development will become a key strategy in tuberculosis control in the future. Recently, mapping of the complete genome sequence of Mycobacterium tuberculosis has been completed [54] , making new vaccine development more promising. Basic research investigating the development of whole-cell live attenuated vaccines, as well as the use of individual antigens delivered by subunit vaccination, is under way [55] . Advances in biotechnology may lead to new, more effective vaccines for tuberculosis [56] . An understanding of the correlates of protective immunity to tuberculosis and identi®cation of surrogate markers of infection, disease, and protection are needed to test vaccine candidates adequately [57] . Also, such surrogate markers could be clinically useful, and represent a vast improvement in current diagnostic tests.
Conclusion
Congenital tuberculosis remains a rare manifestation of a common infectious disease. Recent changes in the epidemiology, including increased rates among foreignborn and young adults in developed countries, as well as the continued rise of disease in developing nations, will result in more cases of congenital tuberculosis. The nonspeci®c clinical presentation among pregnant women and neonates often makes it dif®cult for clinicians to recognize tuberculosis unless there is a high index of suspicion. Important advances in diagnostic techniques have provided rapid detection methods and have improved the speed of culture and sensitivity results. Better methods are still needed, especially for children. As developed countries continue to reduce the incidence of tuberculosis through effective control measures, the emphasis will shift towards prevention and treatment of latent infection in adults and children. An improved basic understanding of the human immune response, including identi®cation of correlates for infection, disease and protection, is needed to facilitate the development of future vaccines and improved diagnostic tests. As a global community, we must address how to combat tuberculosis in areas with limited resources.
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